Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer
PARPi re-maintenance therapy in PSROC might improve prognosis compared to chemotherapy alone, regardless of their genetic mutation status. Patients with re-maintenance therapy might benefit if the interval between the use of PARP inhibitors exceeded 6 months. The structural domains of BRCA mutations with different sensitivity to PARPi might serve as a promising biomarker for optimizing treatment. Re-treatment with PARPi was well-tolerated.
Authors
- Jundong Li (ORCID: https://orcid.org/0000-0002-1878-817X)
- Yunjie Yang (ORCID: https://orcid.org/0000-0002-9616-1663)
- Tao Liu (ORCID: https://orcid.org/0000-0003-1451-5251)
- Li Su (ORCID: https://orcid.org/0000-0002-6453-199X)
- Jihong Liu (ORCID: https://orcid.org/0000-0003-3464-2901)
- Ye Cao
- Yongwen Huang
- Yulin Wang (ORCID: https://orcid.org/0000-0002-3315-1927)
- Xiaoyan Li (ORCID: https://orcid.org/0000-0002-8807-4199)
- Binghong Guo
- Renakezi Tuersun
Institutions
- Sun Yat-sen University (CN)
- Guangdong Pharmaceutical University (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fonc.2024.1512339
- Citations
- 2
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China